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Abstract
Background: Iodine contrast agents (ICAs) are routinely used by radiologists to help guide intra-articular
infiltrations. The aim of this study was to assess the in vitro effects of ICA on platelet function of human autologous
Platelet-Rich Plasma (PRP).
Methods: One hundred thirty-seven consecutive patients with symptomatic femoral-patellar osteoarthritis were
included. All were addressed to our institution for a fluoroscopy-guided intra-articular PRP infiltration of the pathological
femoral-patellar joint. For each patient, 500 μl of PRP were sampled before intra-articular injection. First, PRP samples were
mixed with 50 μl of 2 widely used ICA: Visipaque270® (Iodixanol, n= 58) and Iopamiron200® (Iopamidol, n = 69). PRP
concentration ([PRP]) was measured at different delays of incubation (t = 0, 5, 10, 15, 20 and 30 min) enabling to calculate
PRP ratio (defined as [PRP](t)/[PRP](0mn)) at each delay, for each mixture, in order to quantitatively assess the influence of
ICA on PRP ratio. Second, the PRP samples of 10 additional patients were mixed with Visipaque270®,
Visipaque270®, Iopamiron200® and phosphate buffer saline (PBS: control solution) in order to qualitatively
assess the influence of ICA on platelet aggregation, using ADP, Collagen, Arachidonic acid and TRAP tests.
The surface expression of human P-selectin, a marker of α-granule release, in the PRP + Visipaque270® and
PRP + Iopamiron200® mixtures was finally compared. Repeated-measures ANOVA, classical 2-way ANOVA and
Wilcoxon matched-pairs test were used to study the influence of ICA on PRP quality.
Results: There was no significant change in PRP ratio during the first 30mn of incubation (p = 0.991)
whatever the ICA (p = 0.926). Whatever the aggregation test, there was no significant difference in the percentage of
platelet aggregation between PRP + PBS, PRP + Visipaque270® and PRP + Iopamiron200® (p = 0.998), nor between PRP
+ PBS and PRP + Visipaque320® (p = 0.470). Finally, there was no significant difference in P-selectin expression between
the PRP + Visipaque270® and PRP + Iopamiron200® mixtures (p = 0.500).
Conclusion: At early delays of incubation, Visipaque® and Iopamiron®, which are two widely used ICA for intra-articular
infiltrations, did not influence the in vitro platelet function nor the quality of PRP.
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Background
Osteoarthritis (OA) is a chronic degenerative joint
condition characterized by a progressive destruction of
the articular cartilage leading to pain and functional loss
(Cross et al. 2014). OA affects more than 39 million
people in Europe. These changes lead to a degradation
of the extracellular matrix and a reduction of tissue
cellularity. Furthermore, due to the little proliferative
possibility of articular chondrocytes, cartilage has a li-
mited self-repair ability. Consequently, even minor injur-
ies may progress to important joint degenerations
(Laadhar et al. 2007). Small lesions are generally repaired
by migration of chondrocytes, while larger lesions are
repaired by the formation of a fibrocartilage with im-
paired biomechanical properties Fernandes et al. (2002).
Recent repair treatments have been explored, including
microfracturing or osteochondral allograft transplan-
tation, but they are invasive, with variable prognosis
(Gomoll et al. 2012). Currently, oral nonsteroidal
anti-inflammatory drugs (NSAID), intra-articular corti-
costeroids or hyaluronic acid are widely used to relieve
OA. Unfortunately, these treatments do not have cura-
tive effects on the inflammatory process of OA (Nelson
et al. 2014). To address this question, new repair strat-
egies have been developed. Platelet-rich plasma (PRP) is
a plasma with 3 to 8 times higher platelet concentration
than in the blood, which enables higher concentrations
of active growth factors such as platelet-derived growth
factors, transforming growth factors β and vascular
endothelial growth factor. PRP might promote stem cells
recruitment and fibroblast collagen production. Studies
in human and animal models suggest that PRP would
improve cartilage repair (Sakata et al. 2015). In a recent
meta-analysis of 10 level I randomized controlled trials,
intra-articular PRP injection was found to better relieve
pain and to improve function scores at 1 year
post-injection compared to saline and hyaluronic acid
(Dai et al. 2017). However, contradictory results have been
published (Mascarenhas et al. 2015) but these studies were
performed with different types of PRP on different joints
and included small heterogeneous populations from first to
late stages of OA. Notably, the techniques for intra-articular
PRP infiltration were not standardized: some were
clinically-guided, others imaging-guided. Radiologists are
used to adding iodine contrast agent (ICA) to the injected
substance (for instance corticosteroids or hyaluronic acid)
to improve the precision of fluoroscopy-guided intra-articu-
lar infiltrations. Opacification of the symptomatic joint by
ICA confirms that the needle is correctly positioned. By
analogy, radiologists have come to mix PRP and ICA dur-
ing the imaging-guided procedures in order to ascertain
that PRP is correctly infiltrated. However, the effect of ICA
on platelets is debated and may depend on the type of ICA
Aspelin et al. (2006). In practical applications, knowing that
the quality of PRP is not altered by ICA would encourage
to the use of ICA to better guide the needle. Conversely,
knowing that ICA could alter PRP would discourage the
use of ICA during PRP-related procedure. Thus, the aim of
this study was to investigate the in vitro effect of ICA on
platelet concentration, activation and degranulation from
autologous PRP.
Methods
The institutional ethical committee approved the study.
Signed informed consent was obtained for all patients
who participated.
Patients
From May 2016 to January 2017, a total of 137 consecu-
tive patients were prospectively enrolled in the study. In-
clusion criteria were: age (< 18 years old), radiographically
documented OA in the patellofemoral compartment of
the symptomatic knee (grade 2 and 3 according to the
Kellgren-Lawrence classification), diagnosis of primary
OA confirmed at least 3 months prior to the study, failure
of non-operative treatment performed at least 6 weeks
prior to the study (rehabilitation using analgesic physio-
therapy and eccentric work), indication for intra-articular
PRP injection validated by a sports medicine physician or
an orthopaedic surgeon, infiltration performed at our
musculo-skeletal interventional radiology institution.
Exclusion criteria were: pregnancy, infections, previous
corticosteroid treatment, platelet dysfunction and im-
munodeficiency. None of the 137 patients met the exclu-
sion criteria. The study included 78 men and 59 women
(median age: 45-years old, range 28–64).
PRP preparation
Patients were referred to a clinical pathologist. For each
patient, 22 mL of venous blood was collected in a syr-
inge containing 1.5 mL of citrate anticoagulant. Blood
was centrifuged at 570 g for 8 min and a final volume of
3.5 mL of PRP was recovered in the lower plasma layer.
The platelet concentration factor within the final volume
was 2.5, as verified by platelets counting under an auto-
mated hematology cell analyzer (ABX Pentra 60, Horiba,
Kyoto, Japan). Platelets and leucocytes amounts were
controlled within each PRP sample Dallaudière et al.
(2014). Finally, 500 μl of autologous PRP per patient
were sampled prior to intra-articular PRP injection.
In vitro quantitative assessment
After anonymization of the PRP samples, 500 μl of PRP
were randomly mixed with 50 μl of different ICA (PRP
+ ICA): Iodixanol 270 mg I/mL (Visipaque270®, GE
Healthcare, ChICAgo, Illinois, USA) (n = 58) or Iopami-
dol 200 mg I/mL (Iopamiron200®, Bracco imaging,
Milan, Italy) (n = 69). Visipaque270® is a non-ionic,
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hexa-iodinated solution (iodixanol) with an osmolality of
290 mOsm/kg whose excipients are trometanol, sodium
chlorure, calcium chlorure, sodium edetate calcium,
water and chlorohydrin acid. Iopamiron200® is a non-ionic,
tri-iodinated solution with an osmolality of 413 mOsm/kg
whose excipients are trometanol, sodium hydroxyd, sodium
edetate calcium, water and chlorohydrin acid.
The platelet concentration (G/L) within PRP alone
(t = 0mn) and PRP + ICA at several delays of incuba-
tion was quantified (namely, 5, 10, 15, 20, 30mn).
‘Thirty minutes’ was arbitrarily chosen as the last
point in time because PRP is always infiltrated within
this delay at our institution and because of lack of
enough PRP after this delay for statistical comparisons.
Additionally, in vivo, it is recommended to acquire X-rays
within the 30mn following the infiltration of ICA because
the concentration in ICA continuously decreases as it is
likely absorbed by the synovia (Obermann et al. 1989;
Omoumi et al. 2009). Thus, the interaction between PRP
and ICA should also decrease after this incubation delay.
Then, the pathologist counted the number of platelets
within each sample at each delay of incubation (with an
automated cell analyser) and analysed the morphology of
the platelets (with an optical microscope with a magnifica-
tion of 40) blinded to the clinical data. PRP ratio was de-
fined as the concentration of PRP within the PRP + ICA
mixture at a given time point divided by the initial con-
centration of PRP (PRP ratio = [PRP](t)/[PRP](0mn)).
In vitro qualitative assessment
First, our objective was to compare the platelet function
between two different ICAs (Visipaque270®, Iopamiron200®)
and a control solution (phosphate buffer solution, PBS). Five
patients were included in this part of the study. Their PRP
samples were divided in three equal sub-samples and mixed
with 50 μL of PBS, Visipaque270® and Iopamiron200®. For
each mixture (PRP +PBS, PRP +Visipaque270®, PRP+ Iopa-
miron200®), the platelet aggregation was evaluated according
to 4 tests after a delay of incubation of 30mn, using: (i)
10 μmol/L adenosine diphosphate (ADP, Sigma Aldrich
Chimie, Lyon, France), (ii) 1 mmol/L arachidonic acid (AA,
Nu-Chek-Prep, Elysian, Minnesota, USA), (iii) 25 μmol/L
thrombin receptor activating peptide (TRAP, NeosystemSA,
Strasbourg, France), and (iv) 2 μg/μL of equine tendon colla-
gen (Horm-Chemie collagen, Nycomed Pharma, Munich,
Germany). The tests were achieved in an aggregometer
(APACT® 4004, ELITechGroup, Salon de Provence, France)
according to standard procedures and during an aggregation
test time of 300 s.
Second, we investigated whether a different concentra-
tion in Iode for the same molecule of ICA could change
the platelet function. To do so, we compared the platelet
function of two mixtures: PRP + PBS and PRP + Visipa-
que320® (: iodixanol 320 mg I/mL, instead of 270 mg I/
mL), with the same aggregation tests on five other
patients.
Third, cell surface expressions of P-selectin, which is a
marker of alpha-granule release, in Visipaque270® and
Iopamiron200® mixtures were compared. The measures
were performed on the PRP samples of 5 additional
patients before and after addition of ICA, using VH10,
which is a murine monoclonal antibody produced by
our group Cattaneo et al. (2013). The mean fluorescence
intensity of P-selectin was measured on resting platelets
and after stimulation with 25 μM TRAP, enabling to
calculate the P-selectin expression ratio (defined as the
ratio of mean fluorescence intensity of P-selectin after
TRAP stimulation and before TRAP stimulation).
Statistical analyses
Gaussian distribution was tested with the Shapiro-Wilk
normality test. The initial PRP concentrations (incuba-
tion delay t = 0mn) in the presence of different ICA were
compared using the Mann-Whitney test. The influences
of both ICA and the delay of incubation on PRP ratio
were evaluated with a 2-way ANOVA (with post-hoc
Tukey test for multiple comparisons). The influences of
ICA and the aggregation tests on the percentage of plate-
let aggregation were evaluated with a repeated-measures
2-way ANOVA (with a post-hoc Sidak test for multiple
comparisons). The P-selectin ratios between the PRP +
Visipaque270® and PRP + Iopamiron® mixtures were com-
pared using a non-parametric Wilcoxon matched-pairs
signed rank test.
Data are presented as mean ± standard deviation. A
p-value of less than 0.05 was deemed significant. Statis-
tical analyses were performed using SPSS statistical
software (version 21.0, Chicago, Illinois, USA) and
Graphpad Prism (GraphPad Software, Inc., version 7, La
Jolla, California, USA).
Results
In vitro quantitative assessment
Initially (t = 0mn), there was no significant difference
in [PRP] between the following mixtures: PRP + Visi-
paque270® and PRP + Iopamiron200® mixtures (489.3
+/− 118 G/L versus 460.9 +/− 104.7 G/L, respectively,
p = 0.250) (Fig. 1a).
A 2-way ANOVA was conducted to examine the effect
of ICA, the incubation delay (from 5 to 30mn) and their
interaction on PRP ratio (Fig. 1b). There was no signifi-
cant influence of the incubation delay on PRP ratio
(F(4,128) = 0.069, p = 0.991), neither was there a signifi-
cant influence of the ICA (F(1,128) = 0.009, p = 0.926),
nor a significant influence of their interaction on PRP
ratio (F(4,128) = 2.654, p = 0.057). Table 1 shows the
values of PRP ratio as a function of the incubation delay.
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The optical microscope examination at the end of the
incubation delay (30mn) did not demonstrate morpho-
logical change of the platelets for both ICA (Fig. 1c).
In vitro qualitative assessment
First, the percentage of platelet aggregation within the
different mixtures (PRP + PBS, PRP + Visipaque270® and
PRP + Iopamiron200®) was evaluated after an incubation
of 30mn in the presence of ADP, Collagen, AA and
TRAP (: 4 tests of aggregation).
The solution that was added to PRP did not have a sig-
nificant effect on the percentage of platelet aggregation
(F(2,5) = 0.907, p = 0.414), neither did the interaction
between the aggregation test and the solution added to
PRP (F(6,5) = 0.064, p = 0.998) (Fig. 2a).
When another iodine concentration of Visipaque® was
tested (PRP + Visipaque320® with 320 mg I/mL versus
PRP + PBS) using the 4 same tests of aggregation, the solu-
tion that was added to PRP did not have a significant effect
on the percentage of aggregation (F(1,5) = 2.110, p = 0.166),
neither did the interaction between the aggregation test
and the added solution (F(3,5) = 0.885, p = 0.470) (Fig. 2b).
Post-hoc tests are given in Table 2.
Given the ability of the platelets to release alpha-gran-
ule, the mean fluorescence intensity of P-selectin was
not significantly modified after adding TRAP; neither
was it in the presence of Visipaque270® (p > 0.999) nor
in the presence of Iopamiron200® (p = 0.500). The ratio
of P-selectin expression after adding TRAP and ICA was
not significantly different between Iopamiron200® and
Visipaque270® (0.931 +/− 0.141 versus 0.984 +/− 0.111,
p = 0.500) (Fig. 2c).
Discussion
In this study, we investigated the potential influence of
ICA on platelet function through extensive in vitro
analyses. We demonstrated that the concentration in
PRP was not altered in the presence of ICA during a
delay of incubation of 30mn. We did not observe an al-
teration of the platelet function in the presence of ICA
Fig. 1 In Vitro quantitative assessment. aInitial PRP concentration in the samples (t = 0), in the presence of Visipaque270® and Iopamiron200®. b
Evolution of PRP ratio as a function of time (5 incubation delays: 5, 10, 15, 20, 30mn), for each contrast agent group (Visipaque270® and
Iopamiron200®). c Morphological aspect of platelets before and after exposure to iodine contrast agent: no change was seen
Table 1 PRP ratio in PRP + Visipaque270® and PRP +
Iopamiron200® at different incubation delays
Incubation
Delay (mn)
PRP ratio
Visipaque270® (n = 58) Iopamiron200® (n = 69)
5 0.902 ± 0.028 0.916 ± 0.009
10 0.814 ± 0.014 0.905 ± 0.026
15 0.909 ± 0.020 0.910 ± 0.018
20 0.921 ± 0.025 0.894 ± 0.018
30 0.900 ± 0.028 0.923 ± 0.020
NOTE: PRP ratio is defined as the concentration in PRP in the mixture at each
incubation delay divided by the initial concentration in PRP. Results
are mean ± sd
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according to several aggregation tests. The ability of the
platelets to release alpha-granule was not modified in
the presence of ICA. Altogether, our results suggest that
platelets from PRP samples were not quantitatively and
functionally modified by adding ICA.
The technique for intra-articular infiltration with PRP
lacks standardization when it comes to the platelet con-
centration in PRP samples, the volume of PRP to infil-
trate, the optimal moment for an injection of PRP in the
course of OA, the number of injections to perform and
the adjunction of NSAIDs and/or anaesthetics and/or
ICA. All these technical points could also be optimized
for each joint (Campbell et al. 2015). In our study, we
standardized the collection system with a single centrifu-
gation step and we obtained autologous PRP samples
with a 2.5–3 times higher concentration of platelets, as
recommended in the literature Dallaudière et al. (2014).
Optimizing the chance to correctly target the patho-
logical joint requires guidance by fluoroscopy and valid-
ation of the right position of the needle by opacification
with ICA. For such a controversial treatment as PRP, we
believe that it is crucial to demonstrate that the
substance was well delivered in the joint and not in adja-
cent tissue whether clinical trials or daily routine. The
Fig. 2 In Vitro qualitative assessment. a Platelet aggregation depending on the iodine contrast agent. Three groups were compared: control (PRP
+ phosphate buffer solution), Visipaque270® (PRP + Visipaque270®) and Iopamiron200® (PRP+ Iopamiron200®) (b) Platelet aggregation depending
on the iodine concentration of Visipaque®. Two groups were compared: control (PRP + phosphate buffer solution) and Visipaque320®. The
percentage of platelet aggregation was assessed by 4 tests: in the presence of adenosine diphosphate (ADP), Collagen, Arachidonic acid (Ar. acid)
and thrombin receptor activating peptide (TRAP). c Degranulation: Surface expression of human P-selectin in the presence of PRP + Visipaque270®
or PRP + Iopamiron200®, before and after exposure to 25 μM of TRAP. P selectin expression is expressed as the mean fluorescence intensity
compare to normal. P-selectin expression ratio corresponds to the ratio between expression after TRAP exposure and before TRAP exposure
Table 2 Comparisons in percentage of aggregation between different mixtures, assessed by four aggregation tests
Comparisons Aggregation tests
ADP Collagen AA TRAP
PRP + Iopamiron200® vs. PRP + Visipaque270® > 0.999 0.794 0.940 0.475
PRP + PBS vs. PRP + Visipaque270® 0.839 0.641 0.720 0.895
PRP + PBS vs. PRP + Iopamiron200® 0.817 0.993 0.963 0.748
PRP + PBS vs PRP + Visipaque320® 0.993 0.876 0.761 > 0.999
NOTE. Results are the p-value of the post-hoc tests of the 2-way ANOVA
The different mixtures were: PRP + Iopamiron200®, PRP + Visipaque270®, PRP + Visipaque320®, PRP+ PBS®
Abbreviations: AA arachidonic acid, ADP adenosine diphosphate, PBS phosphate buffer solution, TRAP thrombin recepto activating peptide, vs. versus
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efficacy of PRP may have been ill estimated in previous
studies without the use of ICA because the PRP may
have been delivered outside of the pathological joint.
Radiologists are used to mixing ICA and hyaluronic acid,
or ICA and corticosteroids. By analogy, they routinely
mix ICA and PRP. Yet, the interaction between ICA and
PRP can be questioned. Prior reports suggest that ICA
may have an impact on platelet function. In a study that
investigated the adverse events of several ICA based on
48,261 reports, the authors highlighted the frequency of
bleeding and clotting disorders likely due to alterations
in platelet function (Seong et al. 2013). Cavalli et al.
showed that prostaglandin E2, which can modify platelet
function, was released in the synovial fluid of patients
following a knee arthrography with iothalamate and
iopamidol, which may explain the occurrence of transi-
ent arthritis (Cavalli et al. 1987). In vitro studies showed
that platelet activation was not affected by non-ionic
ICA (Li et al. 1997), but may modify platelet aggregation
and degranulation (Heptinstall et al. 1998). However,
these studies should be carefully analysed because of the
heterogeneous study design, either on PRP or on blood
samples. Herein, our results did not show any in vitro
influence of ICA on PRP within a delay of 30mn.
The benefits of PRP depend on the release of bioactive
compounds at the optimal moment, through platelets
activation and aggregation (Mascarenhas et al. 2015).
We excluded patients who were treated by NSAID treat-
ment in order to limit inappropriate platelet activation
and aggregation. Adding NSAID to PRP decreased the
storage of α-granules and inhibited the activation and
aggregation of platelets. In vivo, the function of platelets
in autologous PRP in patients who were treated by
NSAID is impaired, resulting in a lower quality of PRP
bioactive compounds (Schippinger et al. 2015).
Moreover, the adjunction of anaesthetics or cortico-
steroids to intra-tendinous PRP injections demon-
strated a significant decrease of tenocytes proliferation
and cell viability. These results suggest that adding anaes-
thetics and/or corticosteroids to PRP would compromise
the potential benefits of PRP and the cell viability where
the tendon was injured (Carofino et al. 2012). Further-
more, Bausset et al. showed that, in vitro, anaesthetics
such as Xylocaine® and Naropin® (belonging to the
N-alkyproline anilides group) may compromise PRP po-
tential benefit (Bausset et al. 2014). Herein, the potential
interaction between anaesthetics, ICA and PRP was not
investigated although anaesthetics are always available
during the procedures, at the patient’s request.
In our study, the function of platelets was investi-
gated using aggregation tests and degranulation tests
through the measurement of the P-selectin expression
(Prüller et al. 2011). The measurement of the
P-selectin expression with Flow cytometry is the gold
standard method to evaluate α-granule release after
platelets stimulation by standardized inductors of
platelet activation (Sakata et al. 2015). Bioactive
compounds stored in the α-granules such as
platelet-derived growth factors or transforming growth
factors β, would not have been adequately released if
this pathway had been altered by ICA.
Our study has limitations. First, as a pilot study,
few patients were included in the in vitro qualitative
assessment. The same aggregation tests were per-
formed on 5 patients under 3 conditions (PRP + PBS,
PRP + visipaque270®, PRP + iopamiron200®) and on 5
other patients under 2 conditions (PRP + PBS, PRP +
visipaque320®). Even if the number of patients was
low, the post-hoc tests did not show any tendency to-
wards a difference in the percentage of aggregation
under either of the two conditions. The percentages
of aggregation (and their standard deviation) under all
conditions were very similar to the one under the
control condition (: PRP + PBS alone). Second, our
study groups consisted in patients with heterogeneous
levels of activity, from top-athletes to inactive
patients. However, we clearly defined our inclusion
criteria and we do not believe that the level of acti-
vity could have influenced the interactions between
ICA and PRP in an in vitro study. Third, the methods
of our in vitro qualitative assessment could be ques-
tioned. We did not quantify growth factors and cytokines
in the PRP samples before and after ICA adjunction. Fur-
thermore, we used citrate as an anticoagulant instead of
hirudin though citrate was suspected to mask
pro-aggregatory effects of Iopamiron® in blood samples
(Heptinstall et al. 1998). However, this effect was not ob-
served with ‘hirudinized’ PRP samples instead of ‘hirudi-
nized’ blood samples. Fourth, all the in vitro tests were
performed within a short delay of incubation (t = 30mn).
Even if we did not identify an influence of ICA on PRP
properties during this delay, one cannot eliminate a poten-
tial late interaction after the delay of 30mn. However, it
should be noted that the concentration of ICA within the
joints rapidly decreases with time. Obermann et al.
showed that the best diagnostic quality for knee arthrogra-
phy was obtained when radiographs were acquired within
23mn (Obermann et al. 1989). After this delay, ICA is
absorbed by the synovia and is eliminated through blood
circulation. That is why it is commonly recommended to
limit the delay between ICA infiltration and image acqui-
sition (Omoumi et al. 2009). Finally, the clinical benefit of
adding ICA to PRP compared to PRP alone has not been
studied, neither have the clinical effects on patients from
our series once PRP and ICA were finally injected in the
joint. A randomized controlled trial could be considered
to compare ICA-helped, imaging-guided, intra-articular
PRP infiltration versus direct intra-articular PRP
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infiltrations on knee OA following OARSI clinical trial
recommendations (McAlindon et al. 2015).
To conclude, our results suggest that platelets from
PRP samples were not in vitro quantitatively and qualita-
tively modified by adding ICA. These results need to be
confirmed by in vivo studies with clinical outcome.
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